Clomiphene (Clomid) vs Liothyronine (T3)

Mechanism

Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.

Standard Dosing

Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.

Timing

Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.

Cycle Duration

PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.

Side Effects

• Visual disturbances (blurred vision, floaters, light sensitivity — due to zuclomiphene accumulation)
• Mood swings and emotional lability
• Headache
• Nausea
• Hot flashes
• Gynecomastia (paradoxical, from zuclomiphene's estrogenic activity)
• Elevated estradiol (zuclomiphene accumulation)

Contraindications

• Active liver disease or hepatic dysfunction
• Undiagnosed abnormal uterine bleeding (if prescribed to females)
• Ovarian cysts (females)
• Known hypersensitivity to clomiphene
• Pituitary tumor
• Primary hypogonadism (testicular failure — clomiphene only works in secondary hypogonadism)

Best Stacking Partners

Mechanism

Synthetic triiodothyronine that directly raises active thyroid hormone signaling.

Contraindications

• Cardiac arrhythmia risk
• Do not use without thyroid labs